Laverock Therapeutics Extends Seed Round to £20m

Laverock Therapeutics expands seed funding

Laverock Therapeutics, a gene control company powering the development of disease-responsive advanced therapies, announces the expansion of its seed funding round, taking the total raised to more than £20 million.

Laverock Therapeutics extends seed round to £20m

Life science startup Laverock Therapeutics has extended it seed round to more than £20m with additional backing from new and existing investors. The company, which uses gene control technology to support the development of disease-responsive advanced therapies, raised £13.5m in 2023 seed round. The seed extension investment follows the successful development of the company’s platform. “The Laverock team has been busy over recent months, continui…

Laverock Therapeutics bags additional £6.5m seed money - European Biotechnology Magazine

British targeted gene silencing specialist Laverock Therapeutics Ltd has expanded its seed funding to £20m by a new financing round led by xx and xx. The company said it will use the funds to...l The post Laverock Therapeutics bags additional £6.5m seed money appeared first on European Biotechnology Magazine.